-
Uddannelse
Find uddannelse
Studievejledning
Kvalitet
- Forskning
-
Samarbejde
Virksomheder
Kommuner og regioner
Gymnasier
Myndigheder
-
Om AU
Organisation
Kontakt
Om AU
- Organisation
- Ledelse
- Strategi
- AU i tal
- AU's historie
- Internationalt samarbejde
- Bæredygtighed
- Campus 2.0
- Diversitet og ligestilling
- Ledige stillinger
- Presse
- Kontakt
NEW REVOLUTIONARY ANTIFUNGAL DRUG - A Paradigm Shift In The Treatment Of Invasive Aspergillosis
Projekter: Projekt › Forskning
- Jeppesen, Per Bendix (PI)
Beskrivelse
PulmoPharma’s Puldium™ is new inhalable combination drug for the treatment of invasive aspergillosis in the lungs.
This kind of combination treatments are known to have a very low or not existing risk of developing drug resistance.
Pre-clinical studies have already shown the efficacy of Puldium™ and its clear superiority over the existing used treatments.
We’re currently doing in vitro/in vivo studies and preparing for a toxicology study and Phase IIa studies.
PulmoPharma is actively looking for collaboration in the R&D phase and future commercial partner(s).
This kind of combination treatments are known to have a very low or not existing risk of developing drug resistance.
Pre-clinical studies have already shown the efficacy of Puldium™ and its clear superiority over the existing used treatments.
We’re currently doing in vitro/in vivo studies and preparing for a toxicology study and Phase IIa studies.
PulmoPharma is actively looking for collaboration in the R&D phase and future commercial partner(s).
| Status | Igangværende |
|---|---|
| Effektiv start/slut dato | 01/08/2021 → 31/08/2024 |
| Links | https://pulmopharma.com/home/ |
ID: 258571741